Abstract Library

#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs

Introduction: NETs overexpress somatostatin receptors (SSTRs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cives M

Authors: Mandriani B, Cives M, Pelle' E, Quaresmini D, Ramello M,

Keywords: CAR T cells, adoptive cellular immunotherapy, NETs,

#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes

Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Taboada R

Authors: Taboada R, Riechelmann R, Mauro C, Barros M, Hubner R,

Keywords: neuroendocrine, everolimus, pneumonitis,

#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors

Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, de Paula C, Donadio M, Barros M, Formiga M,

Keywords: hereditary syndrome, neuroendocrine tumors, germline variants,

#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression

Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,

Keywords: neuroendocrine, estrogen, progesterone, clinical trial,

#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Strosberg J

Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,

Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,